These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 8295364

  • 1. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
    Hotehama Y, Mishima HK, Kitazawa Y, Masuda K.
    Jpn J Ophthalmol; 1993; 37(3):270-4. PubMed ID: 8295364
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment.
    Hotehama Y, Mishima HK.
    Jpn J Ophthalmol; 1993; 37(3):259-69. PubMed ID: 8295363
    [Abstract] [Full Text] [Related]

  • 3. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
    Kałuzny J, Sobecki R, Czechowicz-Janicka K, Kecik D, Kałuzny BJ, Stewart JA, Stewart WC.
    Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
    [Abstract] [Full Text] [Related]

  • 5. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.
    Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1312-6; discussion 1316-7. PubMed ID: 8371917
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR.
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [Abstract] [Full Text] [Related]

  • 7. Effects of latanoprost 50 micrograms/ml on Chinese patients with primary open-angle glaucoma and ocular hypertension.
    Liu CJ, Chou JC, Hsu WM, Liu JH.
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):703-9. PubMed ID: 10533300
    [Abstract] [Full Text] [Related]

  • 8. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
    Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP.
    Eye (Lond); 2008 Feb; 22(2):179-83. PubMed ID: 16936646
    [Abstract] [Full Text] [Related]

  • 9. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [Abstract] [Full Text] [Related]

  • 10. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.
    Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1305-11. PubMed ID: 8371916
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C, Romanet JP, Nordmann JP, Allaire C, Groupe d'étude.
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [Abstract] [Full Text] [Related]

  • 12. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM, Bimatoprost Circadian IOP Study Group.
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P.
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [Abstract] [Full Text] [Related]

  • 14. Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost.
    Lupinacci AP, Netland PA, Fung KH, Evans D, Zhao Y.
    Adv Ther; 2008 Mar; 25(3):231-9. PubMed ID: 18369537
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy of pneumatic traheculoplasty (PNT) in patients with open angle glaucoma and ocular hypertension--a preliminary report].
    Wierzbowska J, Stankiewicz A, Romańska Ł.
    Klin Oczna; 2008 Mar; 110(7-9):287-91. PubMed ID: 19112863
    [Abstract] [Full Text] [Related]

  • 16. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE, Lai J.
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [Abstract] [Full Text] [Related]

  • 17. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N, Dolan JW, Kacere RD, Brubaker RF.
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [Abstract] [Full Text] [Related]

  • 18. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.
    Bito LZ, Stjernschantz J, Resul B, Miranda OC, Basu S.
    J Lipid Mediat; 1993 Oct; 6(1-3):535-43. PubMed ID: 8358014
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
    Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost/Timolol Study Group.
    Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
    [Abstract] [Full Text] [Related]

  • 20. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E, Carrasco FG, Costa VP, Casiraghi JF, Vargas E, Sarmina JS, Mayol R.
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.